Edoxaban, an oral direct factor Xa inhibitor, has been found non-inferior to warfarin for
preventing stroke and systemic embolism in patients with non-valvular atrial fibrillation …

Introduction Economic evaluations are becoming increasingly important due to limitations in
economic resources, the expense of many new treatments, the need to allocate health …

Vitamin K antagonists (VKAs) are effective for stroke prevention in patients with atrial
fibrillation (AF) but are difficult to use. Dabigatran etexilate is a prodrug that is rapidly …

The effectiveness and safety of dabigatran for stroke prevention in atrial fibrillation (SPAF)
demonstrated in RE-LY needs to be confirmed in daily care. To evaluate treatment …

In the RE-LY clinical trial, dabigatran presented a better effectiveness/safety profile when
compared to warfarin. However, clinical trials are not very representative of the real-world …

Objectives Several direct oral anticoagulants (DOACs) have been approved by the
European Medicines Agency since 2008. The aim of the present cost-effectiveness-analysis …

Vitamin K antagonists (eg warfarin) are commonly underutilised, due to limitations such as
the need for monitoring, in high-risk atrial fibrillation (AF) patients. We therefore aimed to …

Oral anticoagulants such as warfarin have been used widely for the treatment of venous
thromboembolism and stroke prevention in atrial fibrillation (AF) patients. Warfarin has …

Background—Atrial fibrillation is associated with increased mortality, but the specific causes
of death and their predictors have not been described among patients on effective …

Background—Trial data for the benefits and risks of dabigatran versus warfarin in the
treatment of nonvalvular atrial fibrillation are lacking. We sought to review real-world …